ENTECAVIR- entecavir tablet, film coated
WARNING: SEVERE ACUTE EXACERBATIONS OF HEPATITIS B, PATIENTS CO-INFECTED WITH HIV AND HBV, and LACTIC ACIDOSIS AND HEPATOMEGALY
Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including entecavir. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ].
Limited clinical experience suggests there is a potential for the development of resistance to HIV (human immunodeficiency virus) nucleoside reverse transcriptase inhibitors if entecavir tablet is used to treat chronic hepatitis B virus (HBV) infection in patients with HIV infection that is not being treated. Therapy with entecavir tablet is not recommended for HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy (HAART) [see Warnings and Precautions (5.2) ].
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogue inhibitors alone or in combination with antiretrovirals [see Warnings and Precautions (5.3) ].
Entecavir tablet is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. The following points should be considered when initiating therapy with entecavir tablet:
- In adult patients, this indication is based on clinical trial data in nucleoside-inhibitor-treatment-naïve and lamivudine-resistant subjects with HBeAg-positive and HBeAg-negative HBV infection and compensated liver disease and a more limited number of subjects with decompensated liver disease [see Clinical Studies (14.1) ].
- In pediatric patients 2 years of age and older and weighing greater than 30 kg, this indication is based on clinical trial data in nucleoside-inhibitor-treatment-naïve and in a limited number of lamivudine-experienced subjects with HBeAg-positive chronic HBV infection and compensated liver disease [see Clinical Studies (14.2)].
The recommended dose of entecavir tablets for chronic hepatitis B virus infection in nucleoside- inhibitor-treatment-naÏve adults and adolescents 16 years of age and older is 0.5 mg once daily.
The recommended dose of entecavir tablets in adults and adolescents (at least 16 years of age) with a history of hepatitis B viremia while receiving lamivudine or known lamivudine or telbivudine resistance substitutions rtM204I/V with or without rtL180M, rtL80I/V, or rtV173L is 1 mg once daily.
Decompensated Liver Disease
The recommended dose of entecavir tablets for chronic hepatitis B virus infection in adults with decompensated liver disease is 1 mg once daily.
Table 1 describes the recommended dose of entecavir tablets for pediatric patients 2 years of age or older and weighing at least 10 kg.The oral solution should be used for patients with body weight up to 30 kg.
a Children with body weight greater than 30 kg should receive 10 mL (0.5 mg)
of oral solution or one 0.5 mg tablet once daily.
b Children with body weight greater than 30 kg should receive 20 mL (1 mg) of
oral solution or one 1 mg tablet once daily.
|Recommended Once-Daily Dose of Oral Solution (mL)|
|Body Weight (kg)||Treatment-Naïve Patientsa||Lamivudine-Experienced Patientsb|
|10 to 11||3||6|
|greater than 11 to 14||4||8|
|greater than 14 to 17||5||10|
|greater than 17 to 20||6||12|
|greater than 20 to 23||7||14|
|greater than 23 to 26||8||16|
|greater than 26 to 30||9||18|
|greater than 30||10||20|
In adult subjects with renal impairment, the apparent oral clearance of entecavir decreased as creatinine clearance decreased [see Clinical Pharmacology (12.3) ]. Dosage adjustment is recommended for patients with creatinine clearance less than 50 mL/min, including patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), as shown in Table 2. The once-daily dosing regimens are preferred.
a For doses less than 0.5 mg, entecavir oral solution is recommended.
b If administered on a hemodialysis day, administer entecavir tablet after the hemodialysis session.
|Creatinine Clearance (mL/min)||Usual Dose (0.5mg)||Lamivudine-Refractory or Decompensated Liver Disease (1mg)|
|50 or greater||0.5mg once daily||1mg once daily|
|30 to less than 50||0.25 mg once dailya OR 0.5 mg every 48 hours||0.5mg once daily OR 1mg every 48 hours|
|10 to less than 30||0.15 mg once dailya OR 0.5mg every 72 hours||0.3 mg once dailya OR 1mg every 72 hours|
|Less than 10 Hemodialysis a or CAPD||0.05 mg once dailya OR 0.5mg every 7 days||0.1 mg once dailya OR 1mg every 7 days|
Although there are insufficient data to recommend a specific dose adjustment of entecavir tablets in pediatric patients with renal impairment, a reduction in the dose or an increase in the dosing interval similar to adjustments for adults should be considered.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.